RFK Jr.
HealthPolitics

RFK Jr Makes Another Major Change To Boost ‘Radical Transparency’

RNN Staff

Health and Human Services Secretary Robert F. Kennedy Jr. announced another major overhaul in the federal health system on Friday, as the Food and Drug Administration launched real-time public reporting of adverse drug and vaccine events—a move FDA Commissioner Dr. Marty Makary called a landmark in “radical transparency.”

The change involves the FDA Adverse Event Reporting System (FAERS), the agency’s primary tool for tracking negative reactions to prescription drugs, certain vaccines, and medication errors. While vaccine-specific incidents are still reported through the separate VAERS system, the FAERS public dashboard is now updated in real time and accessible online.

“Adverse event reporting should be fast, seamless and transparent,” said Makary in a statement. “People shouldn’t have to wait months to see this data. We’re eliminating the delay and modernizing how this information is shared.”

According to the FDA, the reform is part of a broader effort to modernize its data infrastructure and identify safety risks more quickly. The agency described it as a “significant step forward” in ensuring real-time protections for public health.

Kennedy’s Reforms at HHS

This is just the latest in a string of major moves by RFK Jr. since taking over at HHS. In June, he overhauled the influential Advisory Committee on Immunization Practices (ACIP), removing long-serving members whom he accused of harboring conflicts of interest.

Among the new appointees to ACIP are prominent dissenters from mainstream medical orthodoxy, including Dr. Robert Malone—an early pioneer in mRNA vaccine research and outspoken critic of the COVID-19 vaccine rollout.

Publicidad

Kennedy’s shakeups have rattled the legacy medical establishment but have been praised by those seeking more independent oversight of public health policy.

A Transparency Push Across the Board

The new FAERS dashboard aims to make it easier for the public, researchers, and doctors to track emerging safety signals in near real-time. The data is collected from health care providers, manufacturers, and consumers, and can be searched by drug name, event type, or date.

HHS said the revamp will eventually expand across all reporting systems, harmonizing how adverse events are tracked and published for public review.

“This is about restoring public trust,” an FDA spokesperson added. “Real-time transparency is a key pillar of that effort.”

Kennedy’s focus on transparency, accountability, and medical freedom continues to define his leadership at HHS—drawing both praise and criticism as he challenges decades-old public health norms.

Ad Blocker Detected!

Refresh